- Poster presentation
- Open Access
5-year safety and efficacy of the once-daily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)
© Lazzarin et al; licensee BioMed Central Ltd. 2010
Published: 8 November 2010
The goal of highly active antiretroviral therapy (HAART) is to suppress HIV RNA to undetectable levels over many years and is primarily dependent on adherence, which is aided by using a once daily regimen with good tolerability and low pill burden. In Study 934 the time to discontinuation for the twice daily regimen of EFV qd + zidovudine/lamivudine bid was significantly shorter than for the once daily regimen (EFV+FTC+TDF) (p=0.003). Herein are the 5 year safety and efficacy data for this once daily regimen.
160 subjects (89% male, 64% white, mean age 41 yrs) in Study 934 originally randomized to the once daily regimen of EFV+FTC+TDF who completed 144 weeks agreed to switch to the single tablet formulation (EFV/FTC/TDF) and remain on study for an additional 96 weeks for a total of 240 weeks.
At baseline (BL), mean HIV RNA= 5.03 log10 c/mL, mean CD4 count= 243 cells/mm3, and 88% had symptomatic HIV or AIDS. After 240 weeks of follow-up:
87% had HIV RNA <400 c/mL and 84% <50 c/mL (M=F); mean CD4 cell increase from BL= 346 cells/mm3. The mean (range) adherence rate was 97% (83-100%). Seventeen subjects discontinued EFV/FTC/TDF: withdrew consent (6); lost to follow-up (5); adverse events (2: osteoporosis (1) and anal cancer (1)); incarceration (2); non-adherence (1); and relocated (1). No patient discontinued due to renal adverse events. Mean change from BL in estimated glomerular filtration rate (e-GFR) by Cockcroft-Gault was -7 mL/min (Mean BL e-GFR, 129 mL/min).
Through 240 weeks, the once daily HAART regimen of EFV+FTC+TDF (dosed as single tablet regimen, EFV/FTC/TDF, from Week 144-240) demonstrated durable antiretroviral efficacy and immunologic recovery in antiretroviral-naïve patients. The decline in e-GFR was mild and not clinically significant.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.